Page last updated: 2024-11-06

indole-3-lactic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Indole-3-lactic acid (ILA) is a tryptophan metabolite produced by the gut microbiota. It has been shown to possess various biological activities, including antioxidant, anti-inflammatory, and neuroprotective effects. ILA is produced through the degradation of tryptophan by specific bacterial enzymes. The compound has gained attention in research due to its potential therapeutic benefits, particularly in the context of gastrointestinal health, inflammation, and brain function. Studies have explored its role in modulating gut microbiota composition, reducing inflammation in inflammatory bowel disease models, and promoting neuronal survival and cognitive function. Further research is ongoing to understand its precise mechanisms of action and potential clinical applications.'

indole-3-lactic acid: RN given refers to cpd without isomeric designation [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

3-(indol-3-yl)lactic acid : A hydroxy monocarboxylic acid that is lactic acid substituted by a 1H-indol-3-yl group at position 3. It is a metabolite of tryptophan. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID92904
CHEMBL ID485011
CHEBI ID24813
SCHEMBL ID578606
MeSH IDM0082106

Synonyms (70)

Synonym
alpha-hydroxy-1h-indole-3-propanoic acid
2-hydroxy-3-(1h-indol-3-yl)propanoic acid
3-(indol-3-yl)lactic acid
CHEBI:24813 ,
MLS000515793
smr000112267
dl-indole-3-lactic acid
indole-3-lactic acid
indole lactate
TIMTEC1_004067
indolelactate
1821-52-9
C02043
dl-indole-3-lactic acid, 99%
I-3000
indole-3-lactate
indolelactic acid
bdbm31881
HMS1545I19
543E5D98-4FD0-4CA4-85A7-2A826EC027F5
BRD-A61478466-001-01-6
CHEMBL485011
3-(3-indolyl)-2-hydroxypropanoic acid
BMSE000409
(1)-alpha-hydroxy-1h-indole-3-propionic acid
832-97-3
3-(3-indolyl)lactic acid
I0031
2-hydroxy-3-(3-indolyl)propionic acid
NCGC00247041-01
2-hydroxy-3-indol-3-ylpropanoic acid
einecs 212-627-9
HMS2267B22
unii-5sw11r7m7m
5sw11r7m7m ,
einecs 217-347-0
FT-0625396
FT-0633858
AKOS015854458
SCHEMBL578606
.beta.-indolyllactic acid
3-(3-indolyl)-2-hydroxypropionic acid
XGILAAMKEQUXLS-UHFFFAOYSA-N
.beta.-(3-indolyl)lactic acid
1h-indole-3-propanoic acid, .alpha.-hydroxy-
3-indolyllactic acid
3-indolelactic acid
F2147-5460
.alpha.-hydroxy-1h-indole-3-propanoic acid
2-hydroxy-3-(3-indolyl)propanoic acid
3-indo-lyllactic acid
indole-3-lactic acid, dl-
3-(3-indolyl)-dl-lactic acid
mfcd00005642
3-indole-lactic acid
CS-0059568
HY-113099
DTXSID70862758
F16362
1h-indole-3-propanoic acid, a-hydroxy-, (a+/-)-
AS-47850
Q27109857
BCP29310
indole-3-lactic acid;indolelactic acid;2-hydroxy-3-(1h-indol-3-yl)propanoic acid
1h-indole-3-propanoic acid, alpha-hydroxy-
indoleglycollic acid
3-amino-3-[5-(3,4-dichlorophenyl)-furan-2-yl]-propionicacid
SB46425
SY277562
mfcd09839710
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
indol-3-yl carboxylic acidAny indolyl carboxylic acid carrying an indol-3-yl or substituted indol-3-yl group.
hydroxy monocarboxylic acidAny monocarboxylic acid which also contains a separate (alcoholic or phenolic) hydroxy substituent.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
VprHuman immunodeficiency virus 1Potency63.09571.584919.626463.0957AID651644
survival motor neuron protein isoform dHomo sapiens (human)Potency0.89130.125912.234435.4813AID1458
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
biosynthetic processKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
response to bacteriumKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
kynurenine metabolic processKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
L-kynurenine catabolic processKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
protein bindingKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
kynurenine-oxoglutarate transaminase activityKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
pyridoxal phosphate bindingKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
protein homodimerization activityKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
glutamine-phenylpyruvate transaminase activityKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
cysteine-S-conjugate beta-lyase activityKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytosolKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
cytoplasmKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
mitochondrionKynurenine--oxoglutarate transaminase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID349604Inhibition of human recombinant KAT1 expressed in Sf9 cells2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1799182hKAT-I Activity Assay from Article 10.1021/jm9000874: \\Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K.\\2009Journal of medicinal chemistry, May-14, Volume: 52, Issue:9
Structural insight into the inhibition of human kynurenine aminotransferase I/glutamine transaminase K.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (66)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (7.58)18.7374
1990's4 (6.06)18.2507
2000's7 (10.61)29.6817
2010's33 (50.00)24.3611
2020's17 (25.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 41.63

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index41.63 (24.57)
Research Supply Index4.29 (2.92)
Research Growth Index5.12 (4.65)
Search Engine Demand Index58.07 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (41.63)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (5.88%)5.53%
Reviews1 (1.47%)6.00%
Case Studies1 (1.47%)4.05%
Observational0 (0.00%)0.25%
Other62 (91.18%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]